Skip to main content
European Commission logo print header

Staff Exchange for Novel applications in 19f magnetic resonance imaging

Descrizione del progetto

Sviluppare mezzi di contrasto per le risonanze magnetiche

Le risonanze magnetiche per immagini (MRI) producono immagini dettagliate degli organi e dei tessuti del corpo. Possono anche fornire nuove informazioni sulla biologia del traffico e della migrazione cellulare. È importante sviluppare mezzi di contrasto per le risonanze magnetiche per rendere la risonanza magnetica una modalità di imaging preclinico e clinico ad alta risoluzione e non invasiva. Il progetto SENATOR, finanziato dall’UE, formerà una rete di organizzazioni internazionali e intersettoriali che lavoreranno a un programma comune di ricerca per sviluppare mezzi di contrasto per risonanze magnetiche basati su nanoparticelle di perfluorocarburi (19F). Il passaggio a una nuova generazione di mezzi di contrasto per risonanze magnetiche è stato stimolato dall’aumento delle evidenze contro i mezzi di contrasto basati su gadolinio (GBCA). È stato consigliato agli operatori sanitari di limitare l’utilizzo di GBCA a situazioni in cui il contrasto è ritenuto assolutamente necessario.

Obiettivo

Magnetic resonance imaging (MRI) is a leading clinical diagnostic technique, which is able to provide whole body imaging, and when individual cells are imaged in living animals, it can provide new insights into the biology of cell trafficking and migration.
For cells to be visualised by MRI, they generally must be labelled to enable their discrimination from surrounding tissue.
The development of magnetic resonance imaging (MRI) contrast agents is therefore an active area of research, where the basis for this interest is the expansion of MRI as a high-resolution and non-invasive important preclinical and clinical imaging modality.
Moreover, there are now new opportunities to developing smart materials with multifunctional abilities including MRI contrast in-built within biomaterial structures, functionalisation with targeting ligands and the carrying of a therapeutic payload. This move towards a new generation of MRI contrast reagents has also been spurred on by the mounting evidence against gadolinium-based contrast agents (GBCAs). They are currently the agents of choice and were considered historically safe and well tolerated until recently.
However, they have been found to accumulate in various tissues of patients who do not have renal impairment, including bone, brain and kidneys. Furthermore, in 2015, the FDA released a new safety announcement regarding GBCAs and the risk of accumulated deposits in the brain following repeated use. Whilst GBCAs are being investigated, they can still be administered but healthcare professionals have been advised to limit the use of GBCA to situations in which contrast is deemed absolutely necessary.This has opened the door to the novelty of using perfluorocarbon (19F) being incorporated inside smart nanoparticles, which can offer unique quantitative signatures for molecular MRI with no competing background signal.

æ

Coordinatore

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES
Contribution nette de l'UE
€ 234 600,00
Indirizzo
Avenida prof egas moniz
1649 028 Lisboa
Portogallo

Mostra sulla mappa

Regione
Continente Área Metropolitana de Lisboa Área Metropolitana de Lisboa
Tipo di attività
Research Organisations
Collegamenti
Altri finanziamenti
€ 0,00

Partecipanti (10)